The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Open accessAbstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). RESULTS: During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although exposure to mTOR inhibitors in the immediate post-transplant period has been associated with delayed bronchial anastomotic healing or anastomotic dehiscence, mTOR inhibitors are now successfully continued up until the time transplant in many centers without complications.(305, 315, 320)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [315]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although exposure to mTOR inhibitors in the immediate post-transplant period has been associated with delayed bronchial anastomotic healing or anastomotic dehiscence, mTOR inhibitors are now successfully continued up until the time transplant in many centers without complications.(305, 315, 320)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [315]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,275
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250
Self-citationKwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 648
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 525
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
The NHLBI Lymphangioleiomyomatosis Registry
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., MAURER, J. R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 466
Self-citationTuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E., Goncharov, D. A., Eszterhas, A., Hunter, D., Glassberg, M., Yeung, R. S., Walker, C., Noonan, D., Kwiatkowski, D., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 433
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 327
McCormack, F. X. (2008) · CHEST Journal · doi:10.1378/chest.07-0898 · Cited by 303
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Khanna D, 2010, Clin Exp Rheumatol, 28, S55
Cited by
Sorted by citations
Items 101–200 of 999
Davies, D. M., Saxena, A., & Kingswood, J. C. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0581-9 · Cited by 78
Integration of mTOR and estrogen–ERK2 signaling in lymphangioleiomyomatosis pathogenesis
Gu, X., Yu, J. J., Ilter, D., Blenis, N., Henske, E. P., & Blenis, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309110110 · Cited by 78
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy
Krymskaya, V. P., & McCormack, F. X. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104245 · Cited by 75
Self-citationGoncharova, E. A., Goncharov, D. A., Fehrenbach, M. L., Khavin, I., Ducka, B., Hino, O., Colby, T. V., Merrilees, M. J., Haczku, A., Albelda, S. Μ., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003840 · Cited by 73
Self-citationKrueger, D. A., Capal, J. K., Curatolo, P., Devinsky, O., Ess, K. C., Tzadok, M., Koenig, M. K., Narayanan, V., Ramos, F. J., Jóźwiak, S., et al. (2018) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.06.007 · Cited by 73
Autophagy, Oxidative Stress and Cancer Development
Taucher, E., Mykoliuk, I., Fediuk, M., & Smolle‐Jüttner, F. (2022) · Cancers · doi:10.3390/cancers14071637 · Cited by 75
Seibert, D. C., Hong, C., Takeuchi, F., Olsen, C. H., Hathaway, O., Moss, J., & Darling, T. N. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-12-201106210-00008 · Cited by 72
Self-citationClinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis
Chang, W., Cane, J., Blakey, J., Kumaran, M., Pointon, K. S., & Johnson, S. R. (2012) · Respiratory Research · doi:10.1186/1465-9921-13-34 · Cited by 72
Komiya, T., Blumenthal, G. M., DeChowdhury, R., Fioravanti, S., Ballas, M. S., Morris, J. C., Hornyak, T. J., Wank, S. A., Hewitt, S. M., Morrow, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0514 · Cited by 71
Adegunsoye, A., Kropski, J. A., Behr, J., Blackwell, T. S., Corte, T. J., Cottin, V., Glanville, A. R., Glassberg, M. K., Griese, M., Hunninghake, G. M., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0238so · Cited by 82
Renal manifestation of tuberous sclerosis complex
Bissler, J. J., & Kingswood, J. C. (2018) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31654 · Cited by 73
mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain
Lisi, L., Aceto, P., Navarra, P., & Russo, C. D. (2015) · BioMed Research International · doi:10.1155/2015/394257 · Cited by 71
Tuberous sclerosis complex: the past and the future
Waele, L. D., Lagae, L. G., & Mekahli, D. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-3027-9 · Cited by 67
Li, C., Lee, P., Sun, Y., Gu, X., Zhang, E. Y., Guo, Y., Wu, C., Auricchio, N., Priolo, C., Li, J., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131080 · Cited by 67
Wu, A. C., Kiley, J. P., Noel, P. J., Amur, S., Burchard, E. G., Clancy, J. P., Galanter, J., Inada, M., Jones, T. K., Kropski, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1895st · Cited by 69
Self-citationNovel strategies for anti-aging drug discovery
Saraswat, K., & Rizvi, S. I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349750 · Cited by 66
Emerging Treatments in the Management of Tuberous Sclerosis Complex
Kohrman, M. H. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.015 · Cited by 66
Badri, K. R., Gao, L., Hyjek, E. M., Schuger, N., Schuger, L. A., Qin, W., Chekaluk, Y. I., Kwiatkowski, D. J., & Zhe, X. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.187.6.663 · Cited by 66
Wataya‐Kaneda, M., Ohno, Y., Fujita, Y., Yokozeki, H., Niizeki, H., Ogai, M., Fukai, K., Nagai, H., Yoshida, Y., Hamada, I., et al. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.1408 · Cited by 66
Non-canonical mTOR-Independent Role of DEPDC5 in Regulating GABAergic Network Development
Swaminathan, A., Hassan-Abdi, R., Renault, S., Siekierska, A., Riché, R., Liao, M., de Witte, P. A. M., Yanicostas, C., Soussi‐Yanicostas, N., Drapeau, P., et al. (2018) · Current Biology · doi:10.1016/j.cub.2018.04.061 · Cited by 70
Gupta, N., Lee, H., Young, L. R., Strange, C., Moss, J., Singer, L. G., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02066-2018 · Cited by 66
Self-citationDrug-Induced Pulmonary Disease
Dulohery, M. M., Maldonado, F., & Limper, A. H. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00071-3 · Cited by 66
A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis
Chang, W., Cane, J., Kumaran, M., Lewis, S., Tattersfield, A., & Johnson, S. R. (2013) · European Respiratory Journal · doi:10.1183/09031936.00167413 · Cited by 65
Metal Ion Signaling in Biomedicine
Rodriguez, R., Müller, S., Colombeau, L., Solier, S., Sindikubwabo, F., & Cañeque, T. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00577 · Cited by 67
Uterine-Specific Loss of Tsc2 Leads to Myometrial Tumors in Both the Uterus and Lungs
Prizant, H., Sen, A., Light, A., Cho, S.-N., DeMayo, F. J., Lydon, J. P., & Hammes, S. R. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1059 · Cited by 65
Targeted treatment trials for tuberous sclerosis and autism: no longer a dream
Şahin, M. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.04.008 · Cited by 66
Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments
Sampson, J. R., & Saxena, A. (2015) · Seminars in Neurology · doi:10.1055/s-0035-1552616 · Cited by 65
Kreuter, M., Herth, F. J. F., Wacker, M. E., Leidl, R., Hellmann, A., Pfeifer, M. A., Behr, J., Witt, S., Kauschka, D., Mall, M. A., et al. (2015) · BioMed Research International · doi:10.1155/2015/123876 · Cited by 63
Tang, Y., Kwiatkowski, D. J., & Henske, E. P. (2022) · Nature Communications · doi:10.1038/s41467-022-32673-7 · Cited by 66
Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis
Takada, T., Mikami, A. S., Kitamura, N., Seyama, K., Inoue, Y., Nagai, K., Suzuki, M., Moriyama, H., Akasaka, K., Tazawa, R., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201605-335oc · Cited by 62
Self-citationChung, E. J., Sowers, A. L., Thetford, A., McKay-Corkum, G. B., Chung, S. I., Mitchell, J. B., & Citrin, D. E. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.07.026 · Cited by 61
Franz, D. N., & Capal, J. K. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0596-2 · Cited by 62
mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex
Franz, D. N., & Krueger, D. A. (2018) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31655 · Cited by 62
Renal Cell Carcinoma in Tuberous Sclerosis Complex
Henske, E. P., Cornejo, K. M., & Wu, C. (2021) · Genes · doi:10.3390/genes12101585 · Cited by 64
The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM)
Xu, K., Zhāng, P., Tian, X., Ma, A., Li, X., Zhou, J., Zeng, N., Gui, Y.-S., Guo, Z., Feng, R., et al. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.10.006 · Cited by 61
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis
El‐Chemaly, S., Taveira‐DaSilva, A. M., Goldberg, H. J., Peters, E., Haughey, M., Bienfang, D. C., Jones, A. M., Julien-Williams, P. A., Cui, Y., Villalba, J. A., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.01.033 · Cited by 61
Self-citationSugalska, M., Tomik, A., Jóźwiak, S., & Werner, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094907 · Cited by 60
Price, T. J., Das, V., & Dussor, G. O. (2016) · Current Drug Targets · doi:10.2174/1389450116666151102095046 · Cited by 60
Anticancer therapy and lung injury: molecular mechanisms
Li, L., Mok, H. Y. I., Jhaveri, P. M., Bonnen, M., Sikora, A. G., Eissa, N. T., Komaki, R. U., & Ghebre, Y. T. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1500180 · Cited by 61
Molecular Basis of Giant Cells in Tuberous Sclerosis Complex
Kwiatkowski, D. J., & Manning, B. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1406613 · Cited by 59
Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis
Maisel, K., Merrilees, M. J., Atochina‐Vasserman, E. N., Lian, L., Obraztsova, K., Rue, R. W., Vasserman, A. N., Zuo, N., Angel, L. F., Gow, A. J., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0123oc · Cited by 59
Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds
Schulz, G., Victoria, C., Kirschning, A., & Steinmann, E. (2020) · Natural Product Reports · doi:10.1039/d0np00024h · Cited by 59
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex
Alesi, N., Khabibullin, D., Rosenthal, D. M., Akl, E. W., Cory, P. M., Alchoueiry, M., Salem, S., Daou, M., Gibbons, W. F., Chen, J. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44229-4 · Cited by 61
Crosstalk between HER2 signaling and angiogenesis in breast cancer
Alameddine, R. S., Otrock, Z. K., Awada, A. H., & Shamseddine, A. I. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff362 · Cited by 58
Sun, Y., Gu, X., Zhang, E., Park, M., Pereira, A. M., Wang, S., Morrison, T. A., Li, C., Blenis, J., Gerbaudo, V. H., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.204 · Cited by 58
Hasbani, D. M., & Crino, P. B. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00052-1 · Cited by 58
Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism
Davis, P. E., Peters, J. M., Krueger, D. A., & Şahin, M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0359-5 · Cited by 58
Obraztsova, K., Basil, M. C., Rue, R. W., Sivakumar, A., Lin, S. M., Mukhitov, A. R., Gritsiuta, A. I., Evans, J. F., Kopp, M. C., Katzen, J. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18979-4 · Cited by 59
Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation
Cao, J., Tyburczy, M. E., Moss, J., Darling, T. N., Widlund, H. R., & Kwiatkowski, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84262 · Cited by 57
Self-citationHigh Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia
Unachukwu, U. J., Chada, K. K., & D'Armiento, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093151 · Cited by 58
Bissler, J. J., & Kingswood, J. C. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287216641353 · Cited by 56
Targeting AMPK for the Alleviation of Pathological Pain
Asiedu, M. N., Dussor, G. O., & Price, T. J. (2016) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-319-43589-3_11 · Cited by 56
Palavra, F., Robalo, C., & Reis, F. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9820181 · Cited by 56
Rationally Designed 3D Hydrogels Model Invasive Lung Diseases Enabling High‐Content Drug Screening
Tam, R. Y., Yockell‐Lelièvre, J., Smith, L. J., Julian, L. M., Baker, A. E. G., Choey, C., Hasim, M. S., Dimitroulakos, J., Stanford, W. L., & Shoichet, M. S. (2018) · Advanced Materials · doi:10.1002/adma.201806214 · Cited by 59
Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review
Sandbank, S., Molho‐Pessach, V., Farkas, A. Z., Barzilai, A., & Greenberger, S. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3262 · Cited by 56
Yuan, E. D., Tsai, P. T., Greene-Colozzi, E. A., Şahin, M., Kwiatkowski, D. J., & Malinowska, I. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds262 · Cited by 55
Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero, R., Coniglio, A., Garaci, F., & Curatolo, P. (2013) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-39-57 · Cited by 55
Autophagy: a potential therapeutic target in lung diseases
Nakahira, K., & Choi, A. M. K. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00072.2013 · Cited by 57
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain
Yousuf, M. S., Shiers, S. I., Sahn, J. J., & Price, T. J. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000030 · Cited by 60
Baldi, B. G., Pereira, C. A. D. C., Rubin, A. S., Santana, A. N. C., Costa, A. N., de Carvalho, C. R. R., Algranti, E., Capitani, E. M. D., Bethlem, E. P., Coletta, E. N. A. M., et al. (2012) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132012000300002 · Cited by 52
Severity and outcome of cystic lung disease in women with tuberous sclerosis complex
Taveira‐DaSilva, A. M., Jones, A. M., Julien-Williams, P. A., Yao, J., Stylianou, M. P., & Moss, J. (2014) · European Respiratory Journal · doi:10.1183/09031936.00088314 · Cited by 54
Self-citationYe, L., Widlund, A. L., Sims, C. A., Lamming, D. W., Guan, Y., Davis, J. G., Sabatini, D. M., Harrison, D. E., Vang, O., & Baur, J. A. (2013) · Aging · doi:10.18632/aging.100576 · Cited by 56
Şahin, M., Henske, E. P., Manning, B. D., Ess, K. C., Bissler, J. J., Klann, E., Kwiatkowski, D. J., Roberds, S. L., Silva, A. J., Hillaire‐Clarke, C. S., et al. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.03.015 · Cited by 57
Self-citationGupta, N., Langenderfer, D., McCormack, F. X., Schauer, D. P., & Eckman, M. H. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-459oc · Cited by 54
Self-citationEvangelisti, C., Cenni, V., & Lattanzi, G. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12928 · Cited by 53
The UK guidelines for management and surveillance of Tuberous Sclerosis Complex
Amin, S., Kingswood, J. C., Bolton, P., Elmslie, F., Gale, D. P., Harland, C. C., Johnson, S. R., Parker, A. P. J., Sampson, J. R., Smeaton, M., et al. (2018) · QJM · doi:10.1093/qjmed/hcy215 · Cited by 52
Genetic Interstitial Lung Disease
Devine, M., & Garcia, C. K. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.001 · Cited by 55
The changing face of a rare disease: lymphangioleiomyomatosis
Harari, S. A., Torre, O., Cassandro, R., & Moss, J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00412-2015 · Cited by 52
Self-citationFu, J., Wang, H., Gao, J., Yu, M., Wang, R., Yang, Z. R., & Zhang, T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9687-7 · Cited by 54
Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Cramer, S., Shi, W., Merrow, A. C., & Pressey, J. G. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000514 · Cited by 52
Nathan, N. R., Wang, J.-A., Li, S., Cowen, E. W., Haughey, M., Moss, J., & Darling, T. N. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.07.018 · Cited by 51
Self-citationTaveira‐DaSilva, A. M., Jones, A. M., Julien-Williams, P. A., Stylianou, M. P., & Moss, J. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.05.012 · Cited by 51
Self-citationRapamycin reversal of VEGF-C–driven lymphatic anomalies in the respiratory tract
Bałuk, P., Yao, L., Servin, J. C. F., Choi, D., Hong, Y., & McDonald, D. M. (2017) · JCI Insight · doi:10.1172/jci.insight.90103 · Cited by 51
Telocytes are the common cell of origin of both PEComas and GISTs: an evidence-supported hypothesis
Ardeleanu, C. M., & Bussolati, G. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01461.x · Cited by 50
Rare lung disease and orphan drug development
Spagnolo, P., du Bois, R. M., & Cottin, V. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70085-7 · Cited by 50
Laforgia, N., SCHETTINI, F., Mattia, D. D., Martinelli, D., Ladisa, G., & Favia, V. (2015) · Neonatology · doi:10.1159/000440939 · Cited by 50
Lymphangioleiomyomatosis: a clinical review
O'Mahony, A. M., Lynn, E., Murphy, D. J., Fabre, A., & McCarthy, C. (2020) · Breathe · doi:10.1183/20734735.0007-2020 · Cited by 53
Carvalho, S. R., Watts, A. B., Peters, J. I., Liu, S., Surasarang, S. H., Escotet-Espinoza, M. S., & Williams, R. O. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.008 · Cited by 50
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cabrera-López, C., Martí, T., Catalá, V., Torres, F., Mateu, S., Ballarín, J., & Torrá, R. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-87 · Cited by 49
Lymphangiomatosis: Clinical Overview
Blei, F. (2011) · Lymphatic Research and Biology · doi:10.1089/lrb.2011.0020 · Cited by 48
Kidney damage due to tuberous sclerosis complex: Management recommendations
Rouvière, O., Nivet, H., Grenier, N., Laurent Zini, A., & Lechevallier, É. (2013) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2013.01.003 · Cited by 48
Gao, L., Yue, M. M., Davis, J., Hyjek, E., & Schuger, L. A. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1559-9 · Cited by 48
Cai, X., Pacheco–Rodriguez, G., Haughey, M., Samsel, L., Xu, S., Wu, H.-P., McCoy, J. P., Stylianou, M. P., Darling, T. N., & Moss, J. (2013) · CHEST Journal · doi:10.1378/chest.13-1071 · Cited by 47
Self-citationmTOR promotes pituitary tumor development through activation of PTTG1
Chen, R., Duan, J., Li, L., Ma, Q., Sun, Q., Ma, J., Li, C., Zhou, X., Chen, H., Jing, Y., et al. (2016) · Oncogene · doi:10.1038/onc.2016.264 · Cited by 47
Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
Hu, S., Wu, X., Xu, W., Tian, X., Yang, Y., Wang, S., Liu, S., Xu, X., & Xu, K. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1178-2 · Cited by 46
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response
Kirk, S. G., Samavati, L., & Liu, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117157 · Cited by 47
Khawar, M. U., Yazdani, D., Zhu, Z., Jandarov, R., Dilling, D. F., & Gupta, N. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.015 · Cited by 45
Accuracy of chest high-resolution computed tomography in diagnosing diffuse cystic lung diseases
Gupta, N., Meraj, R., Tanase, D., James, L. E., Seyama, K., Lynch, D. A., Akira, M., Meyer, C. A., Ruoss, S. J., Burger, C. D., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00570-2015 · Cited by 45
Self-citationAnticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial Hypertension
Morrell, N. W., Archer, S. L., DeFelice, A., Evans, S., Fiszman, M. L., Martin, T., Saulnier, M., Rabinovitch, M., SCHERMULY, R. T., Stewart, D. J., et al. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.109940 · Cited by 45
Guo, Y., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0605 · Cited by 45
Lymphangioleiomyomatosis: Current understanding and potential treatments
Moir, L. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.12.008 · Cited by 46
Development of Molecular Therapies for Venous Malformations
Kangas, J., Nätynki, M., & Eklund, L. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13027 · Cited by 45
Widespread expression of an exogenous gene in the eye after intravenous administration.
Zhu, C., Zhang, Y., & Pardridge, W. M. (2002) · PubMed · Cited by 44
Patient Organizations and Research on Rare Diseases
Ingelfinger, J. R., & Drazen, J. M. (2011) · New England Journal of Medicine · doi:10.1056/nejme1102290 · Cited by 44
Delaney, S. P., Julian, L. M., & Stanford, W. L. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00069 · Cited by 40
Kwiatkowski, D. J., Palmer, M. R., Jóźwiak, S., Bissler, J. J., Franz, D. N., Segal, S., Chen, D., & Sampson, J. R. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.47 · Cited by 42
Krischer, J. P., Gopal-Srivastava, R., Groft, S. C., & Eckstein, D. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2894-x · Cited by 42
Self-citationEstrogen maintains myometrial tumors in a lymphangioleiomyomatosis model
Prizant, H., Taya, M., Lerman, I., Light, A., Sen, A., Mitra, S., Foster, T. H., & Hammes, S. R. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0505 · Cited by 42
Spontaneous pneumothorax in diffuse cystic lung diseases
Cooley, J. C., Lee, G., & Gupta, N. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000391 · Cited by 42
Pimenta, S. P., Baldi, B. G., Acencio, M. M. P., Kairalla, R. A., & de Carvalho, C. R. R. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000400003 · Cited by 41
Metadata
- Authors
- McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H.-S., Krischer, J. P., & Trapnell, B. C.
- Affiliations
- University of Cincinnati (US)
- National Hospital Organization (JP)
- National Institutes of Health (US)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Niigata University Medical and Dental Hospital (JP)
- Oregon Health & Science University (US)
- Cleveland Clinic (US)
- University of Florida (US)
- The University of Texas Health Science Center at Tyler (US)
- National Jewish Health (US)
- Cincinnati Children's Hospital Medical Center (US)
- Harvard University (US)
- United Therapeutics (United States) (US)
- Mayo Clinic (US)
- University of South Florida (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-04-28
- Volume
- 364
- Issue
- 17
- Pages
- 1595-1606
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3118601
- OpenAlex
- W2147028601
- Semantic Scholar
- 0af4a52c455e626ae3c70aa2ba2d64208b19a305
- Cited by
- 1,099
- References
- 27
- Citations by year
- 2026: 38 · 2025: 54 · 2024: 77 · 2023: 70 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 78 · 2018: 77 · 2017: 65 · 2016: 78 · 2015: 87 · 2014: 71 · 2013: 81 · 2012: 68
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Tuberous Sclerosis Alliance
- Pfizer
- LAM Foundation
- Cincinnati Children's Hospital Medical Center
- National Institutes of Health (1ul1rr026314-01, 1UL1RR026314)
- U.S. Food and Drug Administration (FD003362, R01 FD003362)
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL085453, ZIAHL002541)
- National Center for Research Resources (1UL1 RR-026314-01, U54RR019259, UL1-RR026314, U54RR019498, RR019498, RR019259)
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Surgery › Vascular Malformations and Hemangiomas
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lymphangioleiomyomatosis, rapamycin, mTOR signaling, lung function, FEV1, VEGF-D, quality of life, adverse events, drug discontinuation, cystic lung disease
- MeSH terms
- Adult, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Middle Aged, Quality of Life, Vital Capacity, Lymphangioleiomyomatosis, Observation, Sirolimus, Medication Adherence, Intention to Treat Analysis, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
